-+ 0.00%
-+ 0.00%
-+ 0.00%

Corvus publishes corporate presentation highlighting soquelitinib ITK inhibitor pipeline in immune disease and T-cell malignancies

PUBT·08/06/2026 23:19:28
Listen to the news
Corvus publishes corporate presentation highlighting soquelitinib ITK inhibitor pipeline in immune disease and T-cell malignancies
  • Corvus Pharmaceuticals highlighted soquelitinib, an oral, highly selective ITK inhibitor positioned to rebalance immune responses across inflammatory pathways.
  • Pipeline update centered on a Phase 3 peripheral T-cell lymphoma program that is enrolling, with a futility analysis targeted for Q1 2027.
  • Atopic dermatitis program advanced into Phase 2 enrollment, following placebo-controlled Phase 1 results showing efficacy signals with 200 mg BID dosing.
  • Phase 2 asthma study planned to start in 2H 2026; Phase 1b hidradenitis suppurativa study planned to start in September.
  • China partnership with Angel Pharma includes ongoing PTCL and atopic dermatitis studies, with data expected in late 2026 and Q2 2027.


Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Corvus Pharmaceuticals Inc. published the original content used to generate this news brief on August 06, 2026, and is solely responsible for the information contained therein.